ArticleInfection and drug resistance2020
Co-Incidence of Type II Topoisomerase Mutations and Efflux Expression in High Fluoroquinolone Resistant
Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2024Pooled it
- Article
- Harnessing phage-ciprofloxacin synergy to overcome multidrug-resistant infections and biofilm persistence.Archives of microbiology · 2026Article
- Occurrence and Characterization of Antimicrobial-Resistant and VirulentAntibiotics (Basel, Switzerland) · 2026Article
- First comprehensive molecular and phenotypic insights into multidrug resistance and virulence in poultry-associated Enterococcus spp. in Algeria.Molecular biology reports · 2026Article
- Phylogenetic and pathogenic description of Enterococcus faecalis at a Northern Chinese hospital.BMC microbiology · 2025Article
- Advances in drug resistance and resistance mechanisms of four colorectal cancer-associated gut microbiota.PeerJ · 2025Review
- Situational analysis on fluoroquinolones use and characterization of high-level ciprofloxacin-resistantFrontiers in veterinary science · 2023Article
- Determination of efflux activity in Enterococci by Hoechst accumulation assay and the role of zinc oxide nanoparticles in inhibition of this activity.BMC microbiology · 2022Article
- Reduced Susceptibility to Biocides among Enterococci from Clinical and Non-Clinical Sources.Infection & chemotherapy · 2021Article
- Defining Fluoroquinolone Resistance-Mediating Mutations from Non-Resistance Polymorphisms inAntibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction
methodsIn total, 70 clinical
resultsHigh-level resistance to ciprofloxacin was detected in 97.5% of isolates. Sequencing of QRDRs revealed that 65% and 75% of isolates carried mutations in
conclusionCo-incidence of mutation and efflux gene expression in more than half of isolates (13/20) suggests that both mechanisms may play a role in fluoroquinolone resistance. The other unknown mechanisms including different efflux pumps and probably other QRDRs mutations may contribute to fluoroquinolone resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.